Everolimus and Low Dose Cyclosporine combination in DeNovo Kidney Transplant patients

Sailaja,; Sahariah, S; Ch, Umamaheshwar Rao

doi:10.1016/s2212-0017(12)60052-5

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Everolimus and low‐dose CsA combination was successfully used in 15 de‐novo kidney transplant patients (8). Nine patients received injection daclizumab 50 mg in two doses on day 0 and 14 postoperative day as induction therapy.…”

Section: Mtor Inhibitors: the Indian Experiencementioning

confidence: 99%

See 1 more Smart Citation

Clinical application of mTORi based immunosuppression for renal transplantation in India

Chacko

2011

Clinical Transplantation

View full text Add to dashboard Cite

Long-term renal graft survival is hampered by allograft dysfunction and cardiovascular disease resulting from calcineurin inhibitors (CNIs). This has led to the development of immunosuppressive regimens involving mammalian target of rapamaycin (mTOR) inhibitors, sirolimus and everolimus. They seem to provide long-term benefits for kidney function in transplant patients because of their anti-proliferation and anti-tumor properties and absence of nephrotoxicity. Their use has been evaluated in therapeutic regimens aimed at reducing the nephrotoxicity associated with CNIs. Both proactive and reactive strategies have been used. Whether existing strategies of using mTORi in renal transplantation is applicable for Indian patient's remains to be seen. Data on side effect profile, economic viability and the impact of these drugs on infections, particularly in India, are worth documenting. After briefly reviewing available data from India, this article explores the indications, patient populations; timing and practical aspects as well as the safety and efficacy of mTORi-based regimens for renal transplantation and suggests a framework which could allow transplant physicians to tailor its use to their own practice with particular reference to the Indian subcontinent.

show abstract

Section: Mtor Inhibitors: the Indian Experiencementioning

confidence: 99%

“…5 ± 0.21, 452 ± 276 μg/mL, respectively. The mean creatinine clearance at the end of six months was 61.6 mL/min and 24‐h urinary protein level of 281.7 mg/d, which were improved when compared to third month levels of 51.5 mL/month 388 mg/d, respectively (8).…”

Section: Mtor Inhibitors: the Indian Experiencementioning

confidence: 99%

Clinical application of mTORi based immunosuppression for renal transplantation in India

Chacko

2011

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

Everolimus and Low Dose Cyclosporine combination in DeNovo Kidney Transplant patients

Cited by 1 publication

References 0 publications

Clinical application of mTORi based immunosuppression for renal transplantation in India

Clinical application of mTORi based immunosuppression for renal transplantation in India

Contact Info

Product

Resources

About